CompletedNot Applicable

Opiorphin Levels in Fluids of Burning Mouth Syndrome Patients (OPIODYN)

42 participantsStarted 2011-07

Plain-language summary

If epidemiological studies indicate relatively low prevalence reported in the general population, idiopathic burning mouth syndrome (BMS) is a common condition among certain groups of the population: 30% of menopausal women experience oral burning to varying degrees . Despite significant progress made in recent years, in understanding the physiopathogeny, treatment options remain limited and disappointing,resulting in an impairment of the quality of life. Given the chronic nature of idiopathic burning mouth syndrome, the need to identify the causes and effective treatment modalities for subjects suffering is essential.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Clinical diagnosis of Burning Mouth Syndrome * Age between 18 and 80 years * Sensation of pain in the oral mucosa, meeting the diagnostic criteria for BMS (Bergdahl and Anneroth, 1993, Scala 2003) * Signature of informed consent Healthy volunteers * Age between 18 and 80 years * Patient age (+/- 5 years), sex and hormonal status (menopause or not for women) matched with a Burning Mouth Syndrome patient * Signature of informed consent Exclusion Criteria: * Dental or periodontal pain during the month before the visit * General pathology likely to cause mouth pain (diabetes, lupus, shingles, gastric reflux, allergies ...) * Chronic Orofacial pain other than Burning Mouth Syndrome * Treatment with a molecule able to induce oral burning sensations (anti-VEGF, neuroleptics, IEC angiotensin II ...) * Participation concomitantly in biomedical research * No affiliation to a social protection system * Taste disorder other than a dysgeusia linked to Burning Mouth Syndrome * Inability to understand the information note and sign the informed consent

What they're measuring

opiorphin levels in saliva

Timeframe: Day 30

Trial details

NCT IDNCT02686359

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-12